CRISPR Therapeutics AG is a publicly-traded biotechnology company and its stock symbol is ‘CRSP’. According to the dataTable, CRISPR Therapeutics AG’s revenue in the fiscal year ending on December 31 2021 was 12,899 mln. The company had an estimated revenue of 21,400 mln and a reported loss of 1.84 per share for that year.
In the following quarterly results, there was an improvement in revenue but continued losses. On February 15, 2022, CRISPR Therapeutics AG reported 178 mln in revenues with a reported loss of 2.32 per share and an estimated loss of 1.94 per share. On May 9, 2022, the company reported 158 mln in revenues with a reported loss of 2.4 per share and an estimated loss of 2.23 per share. On August 8th 2022, the company reported 94 mln in revenues with a reported loss of 2.24 per share and no estimates were given for that quarter. Finally on November 1st 2022, CRISPR Therapeutics AG reported 0 in revenues with an estimated loss of 2.32 per share for their fourth quarter financial results ending December 31st 2022
Overall it appears that CRISPR Therapeutics AG has seen some improvement in their financial situation over the past year but have yet to turn a profit due to continued losses in each quarter since the beginning of 2021 despite increased revenues when compared to previous quarters from 2020 onwards . As such it appears that more time is needed before we can conclude whether or not this company will be able to turn things around and become profitable on a consistent basis going forward as it continues to focus on its core products and services to remain competitive within its industry sector moving forward into 2023 and beyond.
